Novel insights on GM1 and Parkinson's disease: A critical review

被引:0
|
作者
Maria Fazzari
Erika Di Biase
Giulia Lunghi
Laura Mauri
Elena Chiricozzi
Sandro Sonnino
机构
[1] University of Milan,Department of Medical Biotechnology and Translational Medicine
来源
Glycoconjugate Journal | 2022年 / 39卷
关键词
GM1 ganglioside; GM1 oligosaccharide; Parkinson's disease; Neuronale receptors;
D O I
暂无
中图分类号
学科分类号
摘要
GM1 is a crucial component of neuronal membrane residing both in the soma and nerve terminals. As reported in Parkinson’s disease patients, the reduction of GM1 determines the failure of fundamental functional processes leading to cumulative cell distress up to neuron death. This review reports on the role of GM1 in the pathogenesis of the disease, illustrating the current data available but also hypotheses on the additional mechanisms in which GM1 could be involved and which require further study. In the manuscript we discuss these points trying to explain the role of diminished content of brain GM1, particularly in the nigro-striatal system, in Parkinson’s disease etiology and progression.
引用
收藏
页码:27 / 38
页数:11
相关论文
共 50 条
  • [31] Parkinson's disease recovery by GM1 oligosaccharide treatment in the B4galnt1+/- mouse model
    Chiricozzi, Elena
    Mauri, Laura
    Lunghi, Giulia
    Di Biase, Erika
    Fazzari, Maria
    Maggioni, Margherita
    Valsecchi, Manuela
    Prioni, Simona
    Loberto, Nicoletta
    Pome, Diego Yuri
    Ciampa, Maria Grazia
    Fato, Pamela
    Verlengia, Gianluca
    Cattaneo, Stefano
    Assini, Robert
    Wu, Gusheng
    Alselehdar, Samar
    Ledeen, Robert W.
    Sonnino, Sandro
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [32] GM1 GANGLIOSIDOSIS (LANDING DISEASE)
    HOOFT, C
    SENESAEL, L
    DELBEKE, MJ
    KINT, J
    DACREMONT, G
    EUROPEAN NEUROLOGY, 1969, 2 (04) : 225 - +
  • [33] Parkinson's disease - Improved function with GM1 ganglioside treatment in a randomized placebo-controlled study
    Schneider, JS
    Roeltgen, DP
    Mancall, EL
    Chapas-Crilly, J
    Rothblat, DS
    Tatarian, GT
    NEUROLOGY, 1998, 50 (06) : 1630 - 1636
  • [34] Altered Distribution of the Gangliosides GM1 and GM2 in Alzheimer's Disease
    Pernber, Z.
    Blennow, K.
    Bogdanovic, N.
    Mansson, J. -E.
    Blomqvist, M.
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2012, 33 (2-3) : 174 - 188
  • [35] Insights into the behavioral difference of water in the presence of GM1
    Basu, Ipsita
    Manna, Moutusi
    Mukhopadhyay, Chaitali
    FEBS LETTERS, 2015, 589 (24): : 3887 - 3892
  • [36] GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson's Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson's Disease-Relevant Pathogenic Mechanisms
    Schneider, Jay S. S.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (11)
  • [37] Pesticides and Parkinson's disease - a critical review
    Rumsby, PC
    Brown, T
    Capleton, AC
    Rushton, L
    Koller, KE
    Levy, LS
    TOXICOLOGY, 2004, 202 (1-2) : 71 - 72
  • [38] GM1 GANGLIOSIDOSIS OF FRIESIAN CALVES - A REVIEW
    DONNELLY, WJC
    SHEAHAN, BJ
    IRISH VETERINARY JOURNAL, 1981, 35 (03) : 45 - 55
  • [39] Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease
    Schneider, Jay S.
    Seyfried, Thomas N.
    Choi, Hyo-S.
    Kidd, Sarah K.
    PLOS ONE, 2015, 10 (12):
  • [40] Disease-modifying effects of ganglioside GM1 in Huntington's disease models
    Alpaugh, Melanie
    Galleguillos, Danny
    Forero, Juan
    Morales, Luis Carlos
    Lackey, Sebastian W.
    Kar, Preeti
    Di Pardo, Alba
    Holt, Andrew
    Kerr, Bradley J.
    Todd, Kathryn G.
    Baker, Glen B.
    Fouad, Karim
    Sipione, Simonetta
    EMBO MOLECULAR MEDICINE, 2017, 9 (11) : 1537 - 1557